An ANGPTL4 inhibitory antibody safely improves lipid profiles in non-human primatesResearch in context

Summary: Background: Angiopoietin-like protein 4 (ANGPTL4) inhibition is a promising approach to manage atherogenic dyslipidaemia and residual atherosclerotic cardiovascular disease (ASCVD) risk. Human ANGPTL4 loss-of-function (LoF) is associated with reduced plasma triglyceride (TG), remnant chole...

Cijeli opis

Bibliografski detalji

Glavni autori:	Beryl B. Cummings, Page R. Bouchard, Mark N. Milton, Peter F. Moesta, Vyas Ramanan, John W. Trauger, Eleftheria Maratos-Flier, Andrei Voznesensky, Igor Splawski, Amitabh V. Nimonkar, Keith DiPetrillo, Daniel LaSala, Meihui Pan, Meghan M. Flaherty, Francois Huet, Sukhdeep K. Sahambi, Jijun Dong, Deborah Knee, Regis Cebe, Thomas Huber, Joshua Lehrer-Graiwer, Rebecca A. Juliano, Ethan J. Weiss
Format:	Artigo
Jezik:	Inglês
Izdano:	Elsevier 2025-07-01
Serija:	EBioMedicine
Teme:	MAR001 ANGPTL4 Triglyceride Remnant cholesterol Non-human primates Safety
Online pristup:	http://www.sciencedirect.com/science/article/pii/S2352396425001926
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!